Moreover, we aimed to identify the [18F]-S16 binding patterns in AD patients relative to sex- and age-matched healthy controls (HCs) and the relationship between cerebral tau pathology and hypometabolism patterns with dual [18F]-S16 (T) and [18F]-FDG (N). The gene discussed is MAPT; the disease is Alzheimer disease.